|
发表于 2009-5-12 16:10:03
|
显示全部楼层
Drug treatment can run $1,000s per month
Oncologists increasingly must consider financial as well as medical questions
By DIANE COCHRAN
Of The Gazette Staff
It took one month for Roger Megerth to max out his credit card paying for a cancer drug.
His share of the tab for the oral medication, to treat kidney cancer, jumped from $20 to $988 a month when his insurance plan changed at the beginning of the year.
"I had to Visa charge it," said Megerth, a retired high school English teacher. "That was the only way I could pay for it."
Before Megerth had to find a way to pay for a second month, his physician decided it wasn't the right treatment for him and took him off it.
*
"I'm not the worst-case scenario by any means," Megerth said. "I was fortunate the way it worked out. I think daily about people who are not so fortunate and have several drugs like this and just completely throw their budget out the window."
The high price of the drugs used to treat cancer is a growing problem for U.S. cancer patients and their doctors.
Some patients are basing decisions about treatment on money, and some oncologists are closing or restructuring their practices to compensate for financial losses tied to drug prices.
"I've never seen a provider turn away a patient, but what I've seen is patients making health care decisions based on economics," said Kristin Page Nei, government relations director for the American Cancer Society Action Network in Montana.
The American Cancer Society fields thousands of calls every year from cancer patients looking for financial help, Nei said. Because of eligibility restrictions, the organization can help only about 20 percent of Montanans seeking assistance.
"It's a symptom of a much larger problem," she said. "We need health care reform."
While reform is debated at the national level, local oncologists are looking for ways to adequately treat their patients and stay afloat.
"You can't just talk to patients about their cancer and the toxicity of treatment anymore," said Dr. Patrick Cobb, an oncologist at Hematology Oncology Centers of the Northern Rockies. "You can't focus exclusively on the medical aspect. You have to go into financials."
"None of us are trained to do that," said Cobb, also president of the Community Oncology Alliance, a national nonprofit group. "It's something most oncologists are uncomfortable doing, but, if you don't pay attention, you'll go out of business."
Cobb's practice closed an office in Sheridan, Wyo., last year because it had sunk too far into the red.
Reimbursements from Medicare and Medicaid lagged too far behind the amount the practice was paying to buy drugs from distributors. About 65 percent of Cobb's Sheridan patients were on Medicare or Medicaid.
The Community Oncology Alliance is lobbying Congress to pass legislation that would restructure the way the government pays oncologists for cancer drugs. The group says improvements to the reimbursement system that were promised in the 2003 Medicare Modernization Act never materialized.
Low government reimbursement rates are one reason Cobb's practice is building a multimillion-dollar cancer center on the city's West End. It will offer services, such as radiology, that are profitable and will counter losses on medication, he said.
"eople doing just chemotherapy in the office have had to sell themselves to another entity or do what we're doing now - bring in radiology," Cobb said.
At Billings Clinic, which is also building a multimillion-dollar cancer center, a financial counselor works full-time helping patients find ways to afford drugs.
"The drug itself is the most expensive part of treatment," said Felicia Pinnick, who estimated that two-thirds of Billings Clinic's cancer patients end up in her office.
Susan Jensen needed Pinnick's help when her health insurance wouldn't pay for a breast cancer drug. It cost $20,000 a month.
"Nobody can do that," Jensen said. "I don't know anybody who has an extra $360,000 lying around."
Dr. Tom Purcell, head of Billings Clinic's cancer department, agrees that something needs to change.
But Purcell isn't convinced that increasing payments to oncologists is the answer, because it would probably mean more cost to taxpayers.
"Where would the money come from?" he asked. "There is no more money."
Contact Diane Cochran at dcochran@billingsgazette.com or 657-1287. |
|